Susceptibility of drug-resistant clinical herpes simplex virus type 1 strains to essential oils of ginger, thyme, hyssop, and sandalwood

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 5, 2007, Pages 1859-1862

  Schnitzler, Paul ^a   Koch, Christine ^a   Reichling, Jürgen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ESSENTIAL OIL; THYME OIL;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG SENSITIVITY; GINGER; HERPES SIMPLEX VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS STRAIN;

ACYCLOVIR; DRUG RESISTANCE, VIRAL; GINGER; HERPESVIRUS 1, HUMAN; LAMIACEAE; MICROBIAL SENSITIVITY TESTS; OILS, VOLATILE; SANTALUM; THYMUS PLANT;

EID: 34248383917     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00426-06     Document Type: Article

References (32)

1. Andrei, G., J. Balzarini, P. Fiten, E. De Clercq, G. Opdenakker, and R. Snoeck. 2005. Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin. J. Virol. 79:5863-5869.
2. Carson, C. F., L. Ashton, L. Dry, D. W. Smith, and T. V. Riley. 2001. Melaleuca alternifolia (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis. Antimicrob. Agents Chemother. 48:450-451.
3. Chakrabarti, S., D. Pillay, D. Ratcliffe, P. A. Cane, K. E. Collinghan, and D. W. Milligan. 2000. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J. Infect. Dis. 181:2055-2058.
4. Chen, Y., V. Scieux, V. Garrait, G. Socié, V. Rocha, J. M. Molina, D. Thouvenot, F. Mortin, I. Hocqueloux, L. Garderei, H. Esperou, F. Selimi, A. Dervergie, G. Lelen, M. Aymard, F. Morinet, E. Gluckman, and P. Ribaud. 2000. Resistent herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin. Infect. Dis. 31:927-935.
5. Chibo, D., J. Druce, J. Sasadeusz, and C. Birch. 2004. Molecular analysis of clinical isolates of acyclovir-resistant herpes simplex virus. Antivir. Res. 61: 83-91.
6. Christophers, J., J. Clayton, J. Craske, R. Ward, P. Collins, M. Trowbridge, and G. Darby. 1998. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob. Agents Chemother. 42:868-872.
7. Cox, S. D., C. M. Mann, J. L. Markham, H. C. Bell, J. E. Gustafson, J. R. Warmington, and S. G. Wyllie. 2000. The mode of antimicrobial action of the essential oil of Melaleuca alternifolia (tea tree oil). J. Appl. Microbiol. 88: 170-175.
8. De Clercq, E. 2004. Antiviral drugs in current clinical use. J. Clin. Virol. 30:115-133.
9. Gaudreau, A., E. L. Hill, H. H. Balfour, Jr., A. Erice, and G. Boivin. 1998. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J. Infect. Dis. 178:297-303.
10. Hill, E. L., G. A. Hunter, and M. N. Ellis. 1991. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 35:2322-2328.
11. Inoue, Y., A. Shiraishi, T. Hada, K. Hirose, H. Hamashima, and J. Shimada. 2004. The antibacterial effects of terpene alcohols on Stapylococcus aureus and their mode of action. FEMS Microbiol. Lett. 237:325-331.
12. Knopf, C. W. 1987. The herpes simplex virus type 1 DNA polymerase gene: site of phosphonoacetic acid resistance mutation in strain Angelotti is highly conserved. J. Gen. Virol. 68:1429-1433.
13. Koch, C., J. Reichling, and P. Schnitzler. Essential oils inhibit the replication of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). In R. R. Watson and V. R. Preedy (ed.), The encyclopedia of herbal medicine in clinical practice, in press. CAB International, Wallingford, United Kingdom.
14. Morfin, F., G. Souillet, K. Bilger, T. Ooka, M. Aymard, and D. Thouvenot. 2000. Genetic characterization of thymidine kinase from acyclovir-resistant and acyclovir-susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J. Infect. Dis. 182:290-293.
15. Parris, D. S., R. A. Dixon, and P. A. Schaffer. 1980. Physical mapping of herpes simplex virus type 1 ts mutants by marker rescue: correlation of the physical and genetic maps. Virology 100:275-287.
16. Reichling, J. 2001. Australian and New Zealand tea tree oil as the source of noval antiinfective agents, p. 69-80. In E. Wildi and M. Wink (ed.), Trends in medicinal plant research. Romneya-Verlag, Dossenheim, Germany.
17. Reichling, J., C. Koch, E. Stahl-Biskup, C. Sojka, and P. Schnitzler. 2005. Virucidal activity of a beta-triketone-rich essential oil of Leptospermum scoparium (manuka oil) against HSV-1 and HSV-2 in cell culture. Planta Med 71:1123-1127.
18. Reichling, J., U. Suschke, J. Schneele, and H. K. Geiss. 2006. Antibacterial activity and irritation potential of selected essential oil components - structure-activity relationship. Nat. Prod. Commun. 1:1003-1012.
19. Reusser, P. 1996. Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. J. Hosp. Infect. 3:235-248.
20. Rosen-Wolff, A., T. Ben-Hur, Y. Becker, and G. Darai. 1988. Comparative analysis of the transcripts mapped in the BamHI DNA fragment B of avirulent HSV-1 HFEM, virulent HSV-1 F, and their intratypic recombinant viruses. Virus Res. 10:315-324.
21. Saijo, M., T. Suzutani, E. De Clercq, M. Niikura, A. Maeda, S. Morikawa, and I. Kurane. 2002. Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain. Antiviral Res. 56:253-262.
22. Sasadeusz, J. J., F. Tufuro, S. Safrin, K. Schubert, M. M. Hubinette, P. K. Cheung, and S. L. Sacks. 1997. Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. J. Virol. 71:3872-3878.
23. Schnitzler, P., K. Schön, and J. Reichling. 2001. Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture. Pharmazie 56:343-347.
24. Schöndorf, E., U. Bahr, M. Handermann, and G. Darai. 2003. Characterization of the complete genome of the tupaia (tree shrew) adenovirus. J. Virol. 77:4345-4356.
25. Schuhmacher, A., J. Reichling, and P. Schnitzler. 2003. Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro. Phytomedicine 10:504-510.
26. Shogan, B., L. Kruse, G. B. Mulamba, A. Hu, and D. M. Coen. 2006. Virucidal activity of a GT-rich oligonucleotide against herpes simplex virus mediated by glycoprotein B. J. Virol. 80:4740-4747.
27. Siddiqui, Y. M., M. Ettayebi, A. M. Haddad, and M. N. Al-Ahdal. 1996. Effect of essential oils on the enveloped viruses: antiviral activity of oregano and clove oils on herpes simplex virus type 1 and Newcastle disease virus. Med. Sci. Res. 24:185-186.
28. Sivropoulou, A., C. Nikolaou, E. Papanicolaou, S. Kokkini, T. Lanaras, and M. Arsenakis. 1997. Antimicrobial, cytotoxic, and antiviral activities of Salvia fructicosa essential oil. J. Agric. Food Chem. 45:3197-3201.
29. Söderberg, T., A. Johannson, and R. Gref. 1996. Toxic effects of some conifer resin acids and tea tree oil on human epithelial and fibroblast cells. Toxicology 107:99-109.
30. Stranska, R., R. Schuurman, E. Nienhuis, I. W. Goedegebuure, M. Polman, J. F. Weel, P. M. Wertheim-Van Dillen, R. J. M. Berkhout, and A. M. van Loon. 2005. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J. Clin. Virol. 32:7-18.
31. Whitley, R. J. 2001. Herpes simplex virus, p. 2461-2509. In D. M. Knipe, P. M. Howley, and D. F. Griffin (ed.), Fields virology, 4th ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
32. Whitley, R. J., M. Levin, N. Barton, B. J. Hershey, G. Davis, R. E. Keeney, J. Welchel, A. G. Diethelm, P. Kartus, and S. J. Soong. 1984. Infections caused by herpes simplex in the immunocompromised host: natural history and topical acyclovir therapy. J. Infect. Dis. 150:323-329.